|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-9.60/-3.49
|
企業價值
9.26M
|
資產負債 |
每股賬面淨值
0.48
|
現金流量 |
現金流量率
--
|
損益表 |
收益
709.00K
|
每股收益
0.14
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/21 20:07 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty. |